You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MPS-1 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MPS I, MPS1-S, MPS1-HS Trial in Porto Alegre, London, Salford (SIG-005 (hIDUA Producing Spheres))

Withdrawn
  • MPS I
  • +2 more
  • SIG-005 (hIDUA Producing Spheres)
  • Porto Alegre, Brazil
  • +2 more
Dec 16, 2022

MPS IIIA, Sanfilippo Syndrome, Sanfilippo A Trial in Pittsburgh, North Adelaide, Santiago De Compostela (ABO-102)

Terminated
  • MPS IIIA
  • +3 more
  • Pittsburgh, Pennsylvania
  • +2 more
Jan 11, 2023

Mucopolysaccharidosis Type II (MPS II) Trial in Oakland, Montréal (RGX-121)

Recruiting
  • Mucopolysaccharidosis Type II (MPS II)
  • RGX-121
  • Oakland, California
  • +1 more
Oct 6, 2022

Mucopolysaccharidosis Type II (MPS II) Trial in Brazil, United States (RGX-121)

Recruiting
  • Mucopolysaccharidosis Type II (MPS II)
  • RGX-121
  • Oakland, California
  • +4 more
Dec 22, 2022

Mucopolysaccharidosis Type IIIB, MPS III B Trial in Worldwide (AX 250)

Active, not recruiting
  • Mucopolysaccharidosis Type IIIB
  • MPS III B
  • AX 250
  • Oakland, California
  • +7 more
Jan 16, 2023

Mucopolysaccharidosis II Trial in Salt Lake City, Fairfax (Genetic HMI-203)

Recruiting
  • Mucopolysaccharidosis II
  • Genetic HMI-203
  • Oakland, California
  • +5 more
Jan 26, 2023

Myofascial Pain Syndrome, Trigger Point Pain, Myofascial Trial (conventional therapy, Experimental group 1 : pressure release

Not yet recruiting
  • Myofascial Pain Syndrome
  • Trigger Point Pain, Myofascial
  • conventional therapy
  • +2 more
  • (no location specified)
Jan 9, 2023

Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Oct 31, 2023

MPS III B Trial in Worldwide (AX 250)

Not yet recruiting
  • MPS III B
  • AX 250
  • Oakland, California
  • +4 more
Aug 8, 2022

Study of Patients With MPS IIIA Treated With ABO-102

Enrolling by invitation
  • Mucopolysaccharidosis III-A
  • ABO-102
  • Columbus, Ohio
  • +2 more
Nov 8, 2022

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Chemo-Induced Thrombocytopenia Trial (Hetrombopag)

Not yet recruiting
  • Chemotherapy-Induced Thrombocytopenia
  • (no location specified)
Jul 24, 2023

Mucopolysaccharidosis II, Hunter Syndrome Trial in Pusan, Seoul (GC1123)

Not yet recruiting
  • Mucopolysaccharidosis II
  • Hunter Syndrome
  • GC1123
  • Pusan, Korea, Republic of
  • +2 more
Jun 16, 2022

Advanced / Metastatic Solid Tumor Trial (SR-8541A)

Not yet recruiting
  • Advanced / Metastatic Solid Tumor
  • (no location specified)
Oct 3, 2023

Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)

Recruiting
  • Head Neck Cancer
  • Intratumoral Injection
  • Chicago, Illinois
    University of Illinois at Chicago
Apr 28, 2023

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)

Recruiting
  • Carcinoma
  • +4 more
  • Guangzhou, Guangdong, China
    Lei Zhang
Jun 21, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and

Not yet recruiting
  • Colorectal Neoplasms
  • Beijing, Xicheng Dis, China
    Beijing Friendship Hospital, Capital medical University
Sep 5, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

Mucopolysaccharidosis Type II Observational

Withdrawn
  • Mucopolysaccharidosis II
  • Observational
  • Oakland, California
  • +2 more
Oct 6, 2022

Acute Myeloid Leukemia Trial (Azacitidine, Donor lymphocyte infusion, Camrelizumab)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Mar 15, 2023

Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)

Recruiting
  • Esophageal Neoplasm Metastatic
  • Esophageal Cancer Stage IVb
  • TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
  • +3 more
  • Beijing, Beijing, China
    Cancer hospital, CAMS
Oct 19, 2023